Could a diabetes pill protect heart attack patients from dangerous 'no-reflow'?
NCT ID NCT06342141
First seen Apr 22, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests whether the diabetes drug empagliflozin can reduce the 'no-reflow' phenomenon—where blood flow is not fully restored—in 162 heart attack patients undergoing angioplasty. Participants receive the drug or a placebo before and for 3 days after the procedure. The goal is to see if the drug improves blood flow and reduces heart damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NO-REFLOW PHENOMENON are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute of Cardiology
Mexico City, Mexico City, 14080, Mexico
Conditions
Explore the condition pages connected to this study.